Table 2. Mean and SE of change from baseline of all study participants (mild and moderate).

	Group A (n = 30) Difference (Mean ± SE)	Group B (n = 29) Difference (Mean ± SE)	Group C (n = 30) Difference (Mean ± SE)	(Across 3 groups)aP value	(Between 2 groups)bP value
BCTQs (Baseline)	28.70 ± 1.33	24.69 ± 1.41	26.87 ± 1.54	0.147
WK4-Baseline	−11.53 ± 1.28	−7.03 ± 0.93	−4.50 ± 0.98	<0.001	A vs. B* A vs. C*** B vs. C
WK10-Baseline	−13.40 ± 1.26	−7.21 ± 1.08	−6.40 ± 1.18	<0.001	A vs. B** A vs. C*** B vs. C
WK14-Baseline	−13.30 ± 1.35	−7.86 ± 0.94	−7.48 ± 1.35	0.002	A vs. B** A vs. C** B vs. C
BCTQf (Baseline)	17.30 ± 0.96	15.17 ± 0.87	16.30 ± 0.85	0.250
WK4-Baseline	−6.80 ± 0.82	−3.69 ± 0.45	−2.97 ± 0.51	<0.001	A vs. B** A vs. C*** B vs. C
WK10-Baseline	−7.20 ± 0.84	−4.03 ± 0.46	−3.40 ± 0.70	<0.001	A vs. B** A vs. C** B vs. C
WK14-Baseline	−7.17 ± 0.83	−4.03 ± 0.61	−3.68 ± 0.79	0.002	A vs. B* A vs. C** B vs. C
SNCV (m/s) (Baseline)	31.81 ± 1.08	34.17 ± 1.23	32.77 ± 1.33	0.394
WK4-Baseline	1.04 ± 0.26	1.44 ± 0.29	1.82 ± 0.33	0.172	—
WK10-Baseline	2.16 ± 0.42	1.83 ± 0.21	1.92 ± 0.30	0.760	—
WK14-Baseline	3.09 ± 0.51	2.50 ± 0.30	2.03 ± 0.40	0.189	—
CSA (mm2) (Baseline)	13.19 ± 0.40	12.26 ± 0.41	12.67 ± 0.37	0.261
WK4-Baseline	−1.61 ± 0.16	−1.40 ± 0.22	−1.04 ± 0.17	0.088	—
WK10-Baseline	−1.97 ± 0.21	−1.52 ± 0.20	−1.29 ± 0.19	0.060	—
WK14-Baseline	−2.34 ± 0.25	−1.82 ± 0.24	−1.36 ± 0.21	0.015	A vs. B A vs. C* B vs. C

Group A: 3 sessions of active rESWT; Group B: 1 session of active rESWT; Group C: 3 sessions of sham rESWT.

SE = Standard error, WK = Week, rESWT = Radial Extracorporeal shock wave therapy, BCTQ = Boston Carpal Tunnel Syndrome Questionnaire (s = severity and f = function); SNCV = Sensory nerve conduction velocity; CSA = Cross-sectional area.

*p < 0.05, **p < 0.01, ***p < 0.001.

^aOne-way ANOVA test.

^bBonferroni post hoc tests.